Transgene’s TG4050 Achieves 100% Three-Year Survival in Head and Neck Cancer Trial — Transgene S.A.

Event summary

Transgene and NEC report 100% three-year disease-free survival in Phase 1 trial of TG4050, an individualized neoantigen therapeutic vaccine for head and neck cancer.
Phase 1 results published in Nature Communications show durable neoantigen-specific T cell responses in 73.3% of patients.
TG4050 demonstrated a favorable safety profile with no unexpected findings, encoding up to 30 patient-specific neoantigens.
Phase 1/2 trial (NCT04183166) continues with key milestones including first immunological data in H2 2026 and two-year efficacy data in Q1 2028.

The big picture

Transgene’s success with TG4050 underscores the growing potential of personalized cancer immunotherapies, leveraging AI-driven neoantigen prediction to tailor treatments. The collaboration with NEC highlights the intersection of biotech and advanced IT, particularly in harnessing AI for drug development. This milestone could accelerate the adoption of individualized neoantigen therapeutic vaccines in oncology, addressing a critical unmet need in high-risk cancer patients.

What we're watching

Clinical Validation: Whether TG4050 can sustain its 100% disease-free survival rate in the larger Phase 2 trial.
Regulatory Pathway: The pace at which Transgene advances TG4050 toward regulatory approval given the promising Phase 1 data.
Commercialization Strategy: How Transgene plans to scale production and distribution of individualized neoantigen vaccines like TG4050.